DelveInsight's analysis estimates that the postherpetic neuralgia market is expected to show positive growth, mainly attributed to increased incidence and the anticipated launch of novel therapies
Rhenman & Partners Asset Management AB boosted its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) by 14.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 800,000 shares of the biopharmaceutical company’s stock after acquiring an additional 100,000 […]
Dynavax Technologies Co. (NASDAQ:DVAX – Get Free Report) was the target of a significant growth in short interest in May. As of May 15th, there was short interest totalling 22,700,000 shares, a growth of 15.7% from the April 30th total of 19,620,000 shares. Based on an average daily volume of 2,070,000 shares, the days-to-cover ratio […]
StockNews.com lowered shares of Dynavax Technologies (NASDAQ:DVAX – Free Report) from a buy rating to a hold rating in a research report report published on Tuesday morning. Other equities analysts have also issued research reports about the company. HC Wainwright reiterated a buy rating and set a $29.00 price objective on shares of Dynavax Technologies […]
StockNews.com upgraded shares of Dynavax Technologies (NASDAQ:DVAX – Free Report) from a hold rating to a buy rating in a research report sent to investors on Monday morning. A number of other equities analysts have also commented on the company. The Goldman Sachs Group started coverage on Dynavax Technologies in a research note on Thursday, […]